CIK 0000943819 · Large accelerated filer
RESMED INC
Sign in to watch- Tickers
- RMD RSMDF
- Exchange
- NYSE, OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 980152841
- Phone
- 8587462400
- Business address
- 9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA, 92123
Securities
- RMD ResMed Inc. Common Stock NYSE
- RSMDF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,744,605
- in 5 filings, $3.7M under 10b5-1 plans
Net −$3,744,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −1,000 | $254.30 | $254K | 84,495 |
| 2026-02-09 | Farrell Michael J. Chairman and CEO | Option exercise 10b5-1 | +4,991 | $146.34 | $730K | 471,214 |
| 2026-02-09 | Farrell Michael J. Chairman and CEO | Sale 10b5-1 | −4,991 | $273.78 | $1.4M | 466,223 |
| 2026-02-09 | Farrell Michael J. Chairman and CEO | Option exercise · ResMed Common Stock Options 10b5-1 | −4,991 | 44,921 | ||
| 2026-02-04 | FARRELL PETER C Director | Sale 10b5-1 | −2,000 | $251.31 | $503K | 64,773 |
| 2026-02-04 | Rider Michael J Global General Counsel | Sale 10b5-1 | −50 | $260.00 | $13K | 9,691 |
| 2026-02-02 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −1,000 | $257.03 | $257K | 85,495 |
| 2026-01-07 | FARRELL PETER C Director | Sale 10b5-1 | −2,000 | $248.83 | $498K | 66,773 |
| 2026-01-07 | Farrell Michael J. Chairman and CEO | Option exercise 10b5-1 | +4,991 | $146.34 | $730K | 471,214 |
| 2026-01-07 | Farrell Michael J. Chairman and CEO | Sale 10b5-1 | −4,991 | $248.46 | $1.2M | 466,223 |
| 2026-01-07 | Farrell Michael J. Chairman and CEO | Option exercise · ResMed Common Stock Options 10b5-1 | −4,991 | 49,912 | ||
| 2026-01-02 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −1,000 | $241.75 | $242K | 86,495 |
| 2026-01-02 | Rider Michael J Global General Counsel | Sale 10b5-1 | −50 | $241.75 | $12K | 9,741 |
| 2025-12-08 | Farrell Michael J. Chairman and CEO | Option exercise 10b5-1 | +4,991 | $146.34 | $730K | 471,214 |
| 2025-12-08 | Farrell Michael J. Chairman and CEO | Sale 10b5-1 | −4,991 | $251.41 | $1.3M | 466,223 |
| 2025-12-08 | Farrell Michael J. Chairman and CEO | Option exercise · ResMed Common Stock Options 10b5-1 | −4,991 | 54,903 | ||
| 2025-12-03 | FARRELL PETER C Director | Sale 10b5-1 | −2,000 | $251.47 | $503K | 68,773 |
| 2025-12-01 | Rider Michael J Global General Counsel | Sale 10b5-1 | −50 | $244.16 | $12K | 9,791 |
| 2025-12-01 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −1,000 | $244.16 | $244K | 87,495 |
| 2025-11-25 | De Witte Jan Director | Sale 10b5-1 | −2,055 | $255.00 | $524K | 4,261 |
Page 3 of 18 · 355 trades